The article examines how America's current strategies to decrease rising prescription drug costs could have unintended consequences for American medicine systems and pharmaceutical companies. It looks at both positive and negative aspects of these policies, while cautioning that they may cause certain unwelcome side-effects in both areas mentioned. By examining this issue from all angles, it warns readers of potential unanticipated implications from these strategies while encouraging citizens to understand their potential effects before fully subscribing to them.